Premium
Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours
Author(s) -
Sabattini S.,
Barzon G.,
Giantin M.,
Lopparelli R. M.,
Dacasto M.,
Prata D.,
Bettini G.
Publication year - 2017
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12246
Subject(s) - mast cell , receptor tyrosine kinase , tyrosine kinase , receptor , mast (botany) , cancer research , chemistry , medicine , pathology , immunology
This study investigated Kit receptor dysregulations (cytoplasmic immunohistochemical expression and/or c‐ KIT mutations) in cats affected with splenic mast cell tumours. Twenty‐two cats were included. Median survival time was 780 days (range: 1–1219). An exclusive splenic involvement was significantly ( P = 0.042) associated with longer survival (807 versus 120 days). Eighteen tumours (85.7%) showed Kit cytoplasmic expression (Kit pattern 2, 3). Mutation analysis was successful in 20 cases. Fourteen missense mutations were detected in 13 out of 20 tumours (65%). Eleven (78.6%) were located in exon 8, and three (21.6%) in exon 9. No mutations were detected in exons 11 and 17. Seven mutations corresponded to the same internal tandem duplication in exon 8 (c.1245_1256dup). Although the association between Kit cytoplasmic expression and mutations was significant, immunohistochemistry cannot be considered a surrogate marker for mutation analysis. No correlation was observed between c‐Kit mutations and tumour differentiation, mitotic activity or survival.